T4/T3 combination therapy: what it is, who it helps, and how a trial works.

Why add T3 at all?

A healthy thyroid releases both hormones, roughly 80 percent T4 and 20 percent T3 by weight. Levothyroxine supplies only T4 and asks the body to make all of its T3 by conversion. Most people manage. Some do not: they run a high-normal free T4, a low-normal or low free T3, and symptoms such as fatigue, cognitive slowing, cold intolerance, or weight gain that never fully lift. Adding T3 directly bypasses the conversion step.

Synthetic liothyronine (brand name Cytomel, also available as a generic) is absorbed quickly and has a half-life of about one day, so blood levels rise and fall within hours of a dose. That is the main practical difference from levothyroxine, and the reason dosing has to be handled carefully.

What the guidelines say

The 2021 joint consensus from the ATA, BTA, and ETA reviewed the randomized trials to date and found no consistent benefit of combination therapy across all hypothyroid patients, while noting that the trials were short, used fixed ratios, and did not select the patients most likely to respond. It concluded that a trial of combination therapy may be considered for adults who have a normal TSH on a stable, full replacement dose of levothyroxine (at least 1.2 mcg per kilogram per day), who still have hypothyroid symptoms, and who have a low serum T3 on levothyroxine alone. It recommended giving liothyronine at least twice a day and running any trial for a long enough period to judge it fairly.

The JCEM crossover trial described in our levothyroxine article points the same direction: no difference for the average patient, but a clear preference for T3-containing therapy among the most symptomatic third, half of whom chose combination therapy.

A genetic variant in the DIO2 gene (Thr92Ala), which affects the enzyme that converts T4 to T3, has been associated in some studies with poorer wellbeing on levothyroxine and better response to combination therapy. Those findings have not been consistently replicated, and genetic testing is not yet a standard part of deciding who gets a trial.

How a trial is usually structured

The principle is to keep total thyroid hormone roughly the same while shifting some of it from T4 to T3, so that TSH stays in range and free T3 rises modestly.

These are illustrations from the published literature, not a prescription. Doses are individualized by weight, labs, age, and heart health.

Monitoring: labs are rechecked about six weeks after a change, ideally drawn before the morning T3 dose or a consistent number of hours after it, because free T3 peaks two to four hours after each dose. A trial of three to six months is usually long enough to know whether symptoms and quality of life improved; many clinicians use a validated symptom questionnaire at the start and end so the judgment is not just impression.

Who should be cautious

Because T3 acts fast and directly on the heart and bone, combination therapy is generally not advised for people with a history of arrhythmia such as atrial fibrillation, ischemic heart disease, or osteoporosis, and it is not recommended during pregnancy, in children, or in frail older adults. Over-replacement, meaning a suppressed TSH or a free T3 above range, carries real risks of atrial fibrillation and bone loss and is the thing a careful clinician watches for most.

Side effects of too much T3 are those of hyperthyroidism: palpitations, anxiety, tremor, sweating, insomnia, and loose stools. They usually mean the dose or the timing needs adjustment rather than that the approach has failed.

Practical tips patients find useful

• Liothyronine is best taken on a schedule, for example on waking and early afternoon. A late dose can disturb sleep.
• Keep the levothyroxine habits you already have: empty stomach, away from coffee, calcium, and iron.
• Sustained-release T3 is not FDA-approved in the United States; it is available only from compounding pharmacies, which is one reason some patients and clinicians choose desiccated thyroid.
• Do not start, stop, or adjust T3 on your own. The margin between the right dose and too much is narrow.

Questions to bring to your appointment

• My TSH is normal but I still feel hypothyroid. Have we checked whether my free T3 is low?
• Would I meet the criteria the thyroid associations describe for a trial of combination therapy?
• How would we measure whether it worked, and when would we decide?
• Is there anything in my heart or bone health that makes T3 a poor fit for me?

Combination therapy is not better than levothyroxine for everyone, and it is not a cure-all. For a well-chosen patient under good monitoring, it can be the difference between "normal labs" and actually feeling well.